Emery Bresnick

美国威斯康辛大学

Emery Bresnick is Professor of Cell and Regenerative Biology, Founding Director of UW-Madison Blood Research Program and Co-Director of the Cancer Genetic/Epigenetic Mechanisms Program of the Carbone Cancer Center. His multidisciplinary research discovered genetic/epigenetic mechanisms that unveiled new paradigms of blood stem and progenitor cell development/function and human disease diagnostic strategies. Dr. Bresnick has published >150 peer-reviewed publications (18702 citations; H index: 59), and his work has been continuously NIH-funded since 1997. His national/international leadership contributions include chair of study sections, advisory and editorial board positions and mentoring program director. Dr. Bresnick has been honored with multiple awards including Leukemia and Lymphoma Society Scholar, NIH Research Career Development, NIH MERIT R37, Shaw Scholar, Romnes, and Kellett Mid-Career awards. His trainees have received distinguished awards including Herbert Tabor Young Investigator, Leukemia and Lymphoma Society Senior Fellow, ASH Scholar and Goldwater Scholar. Dr. Bresnick has contributed significantly as an educator, having developed the course Fundamentals of Stem Cell and Regenerative Biology, participated in diverse graduate courses and taught endocrine pharmacology to medical students. He is passionate about training the next generation of scientists/scholars and building alliances to enhance training opportunities, unite fields and achieve synergistic outcomes.

Dr. Bresnick’s group discovered genetic mechanisms that govern development of the hematopoietic system. Transcriptional enhancers operating in these mechanisms are essential for hematopoiesis in humans and mice, embryonic development, and their disruption causes cancer and other blood diseases. Mechanistic studies unveiled new paradigms to explain hematopoietic stem cell generation, myeloid progenitor cell fate decisions and erythrocyte development. Aberrations in GATA2 expression resulting from germline mutation of one of these enhancers (+9.5) (or coding region mutations) cause “GATA2-deficiency syndrome”, which involves immunodeficiency, bone marrow failure and predisposition to develop myelodysplastic syndromes and acute myeloid leukemia.